# UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

> **NCT00045175** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 33 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** 7-hydroxystaurosporine
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00045175
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2013-06
- **Final completion:** —
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2016-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045175, "UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00045175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*